Eisai and the EORTC are developing indisulam, a sulfonamide which inhibits progression from the G(1) phase of the cell cycle, for the potential treatment of cancer [338089]. As of January 2001, indisulam was in phase II trials in Europe for the treatment of solid tumors, and phase II US studies have been ongoing since March 2001 [400862]. In 2001, clinical development of the drug in Japan was scheduled to begin in fiscal year 2002 [396633].
Indisulam. Eisai / C. T. Supuran. - In: IDRUGS. - ISSN 1369-7056. - STAMPA. - 5:(2002), pp. 1075-1079.
Indisulam. Eisai.
SUPURAN, CLAUDIU TRANDAFIR
2002
Abstract
Eisai and the EORTC are developing indisulam, a sulfonamide which inhibits progression from the G(1) phase of the cell cycle, for the potential treatment of cancer [338089]. As of January 2001, indisulam was in phase II trials in Europe for the treatment of solid tumors, and phase II US studies have been ongoing since March 2001 [400862]. In 2001, clinical development of the drug in Japan was scheduled to begin in fiscal year 2002 [396633].File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.